Stock PBYI PUMA BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Real-time Estimate Cboe BZX
Other stock markets
 07:49:04 03/05/2024 pm IST 		5-day change 1st Jan Change
5.045 USD +1.71% Intraday chart for Puma Biotechnology, Inc. +1.39% +17.55%
02/05 Transcript : Puma Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024
02/05 Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Puma Biotech: Q1 Earnings Snapshot
AQ
Puma Biotechnology Reports First Quarter Financial Results
BU
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
BU
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(4)
AQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
BU
Puma Biotechnology : Corporate Presentation
PU
Puma Biotech: Q4 Earnings Snapshot
AQ
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
BU
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
BU
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
BU
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
BU
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
BU
HER2-mutant Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
Puma Biotech: Q3 Earnings Snapshot
AQ
Puma Biotechnology Reports Third Quarter 2023 Financial Results
BU
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PBYI Stock
  4. News Puma Biotechnology, Inc.
  5. Press Releases